Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Page 1
Late Relapses of Membranous Nephropathy: A Case Series.
Peleg Y, Bomback AS, Canetta PA, Radhakrishnan J, Appel GB, Ahn W. Peleg Y, et al. Among authors: appel gb. Kidney360. 2021 Apr 28;2(6):974-982. doi: 10.34067/KID.0007712020. eCollection 2021 Jun 24. Kidney360. 2021. PMID: 35373076 Free PMC article.
Fourteen patients (88%) received immunosuppression during their initial presentation and late relapse. Patients had favorable long-term renal outcomes over a median 21 (range, 12-56) year follow-up period, with 14 patients (88%) in remission at study conclusion and a media …
Fourteen patients (88%) received immunosuppression during their initial presentation and late relapse. Patients had favorable long-term …
Concurrent Anti-Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series.
Ahmad SB, Santoriello D, Canetta P, Bomback AS, D'Agati VD, Markowitz G, Ahn W, Radhakrishnan J, Appel GB. Ahmad SB, et al. Among authors: appel gb. Am J Kidney Dis. 2021 Aug;78(2):219-225.e1. doi: 10.1053/j.ajkd.2020.11.023. Epub 2021 Jan 7. Am J Kidney Dis. 2021. PMID: 33421452
We report a series of such patients, characterizing their long-term follow up. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: Twelve patients referred to 1 medical center between 2001 and 2019 with anti-GBM disease and MN whose clinical characteristics and course w …
We report a series of such patients, characterizing their long-term follow up. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: …
Persistent Disease Activity in Patients With Long-Standing Glomerular Disease.
Delbarba E, Marasa M, Canetta PA, Piva SE, Chatterjee D, Kil BH, Mu X, Gibson KL, Hladunewich MA, Hogan JJ, Julian BA, Kidd JM, Laurin LP, Nachman PH, Rheault MN, Rizk DV, Sanghani NS, Trachtman H, Wenderfer SE, Gharavi AG, Bomback AS; CureGN Consortium. Delbarba E, et al. Kidney Int Rep. 2020 Mar 20;5(6):860-871. doi: 10.1016/j.ekir.2020.03.017. eCollection 2020 Jun. Kidney Int Rep. 2020. PMID: 32518868 Free PMC article.
CONCLUSION: Disease activity did not differ among patients with shorter versus longer duration of disease. Such survivor patients, with long-term but persistent disease, are potentially highly informative for understanding the clinical course and pathogenesis of GN and may …
CONCLUSION: Disease activity did not differ among patients with shorter versus longer duration of disease. Such survivor patients, with long …
Treatment of Rapidly Progressive Glomerulonephritis in the Elderly.
Appel GB, Lau WL. Appel GB, et al. Blood Purif. 2018;45(1-3):208-212. doi: 10.1159/000485367. Epub 2018 Jan 26. Blood Purif. 2018. PMID: 29478072 Free article.
Although this regimen has diminished the immediate mortality rate of RPGN, its intermediate and long-term adverse effects are not insignificant. Attempts to minimize toxicity and improve efficacy have been made through the years to allow physicians some options for therapy …
Although this regimen has diminished the immediate mortality rate of RPGN, its intermediate and long-term adverse effects are not ins …
The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.
Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, Gipson DS, Kretzler M, Troost JP, Lieske JC. Hogan MC, et al. Among authors: appel gb. Kidney Int. 2016 Nov;90(5):1080-1089. doi: 10.1016/j.kint.2016.06.020. Epub 2016 Aug 12. Kidney Int. 2016. PMID: 27528553 Free PMC article.
However an estimating equation was developed to derive 24-hour urine protein excretion from random urine protein creatinine ratio values with improved precision. The long-term prognostic value of log(10)-transformed random protein creatinine ratios values requires future s …
However an estimating equation was developed to derive 24-hour urine protein excretion from random urine protein creatinine ratio values wit …
A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group. Fervenza FC, et al. Among authors: appel gb. Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12. Nephron. 2015. PMID: 26087670 Clinical Trial.
The membranous nephropathy trial of rituximab (MENTOR) hypothesizes that B-cell targeting with rituximab is non-inferior to CSA in inducing long-term remission of proteinuria. METHODS AND DESIGN: Patients with idiopathic membranous nephropathy, proteinuria 5 g/24 h, and a …
The membranous nephropathy trial of rituximab (MENTOR) hypothesizes that B-cell targeting with rituximab is non-inferior to CSA in inducing …
Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis.
Morris HK, Canetta PA, Appel GB. Morris HK, et al. Among authors: appel gb. Nephrol Dial Transplant. 2013 Jun;28(6):1371-6. doi: 10.1093/ndt/gfs447. Epub 2012 Dec 11. Nephrol Dial Transplant. 2013. PMID: 23233523 Review.
Current treatment of lupus nephritis consists of both induction and maintenance therapy, with the latter being designed to consolidate remissions and prevent relapses. Long-term maintenance treatment with intravenous cyclophosphamide was effective but associated with consi …
Current treatment of lupus nephritis consists of both induction and maintenance therapy, with the latter being designed to consolidate remis …
Diagnosis and treatment of lupus nephritis flares--an update.
Sprangers B, Monahan M, Appel GB. Sprangers B, et al. Among authors: appel gb. Nat Rev Nephrol. 2012 Dec;8(12):709-17. doi: 10.1038/nrneph.2012.220. Epub 2012 Nov 13. Nat Rev Nephrol. 2012. PMID: 23147758 Review.
Lupus nephritis flares are independently associated with an increased risk of deterioration in renal function; prevention of renal flares might, therefore, also decrease long-term morbidity and mortality. Appropriate immunosuppressive maintenance therapy might lead to a de …
Lupus nephritis flares are independently associated with an increased risk of deterioration in renal function; prevention of renal flares mi …
Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB. Bomback AS, et al. Among authors: appel gb. J Am Soc Hypertens. 2012 Sep-Oct;6(5):338-45. doi: 10.1016/j.jash.2012.07.003. J Am Soc Hypertens. 2012. PMID: 22995802 Clinical Trial.
Aldosterone levels increase in 30%-40% of patients on angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers over the long term. This "aldosterone breakthrough" may carry important clinical consequences given aldosterone's nonepithelial, pro-fibrotic …
Aldosterone levels increase in 30%-40% of patients on angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers over the …
Idiopathic membranous nephropathy: clinical and histologic prognostic features and treatment patterns over time at a tertiary referral center.
Sprangers B, Bomback AS, Cohen SD, Radhakrishnan J, Valeri A, Markowitz GS, D'Agati V, Appel GB. Sprangers B, et al. Among authors: appel gb. Am J Nephrol. 2012;36(1):78-89. doi: 10.1159/000339628. Epub 2012 Jun 27. Am J Nephrol. 2012. PMID: 22739228
BACKGROUND: Idiopathic membranous nephropathy (i-MN) is a leading cause of nephrotic syndrome in adults and results in end-stage renal disease in approximately one third of patients. There are few large, long-term US studies evaluating clinical and histologic prognostic fa …
BACKGROUND: Idiopathic membranous nephropathy (i-MN) is a leading cause of nephrotic syndrome in adults and results in end-stage renal disea …
30 results